NEW YORK, Dec. 10, 2009 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, announced today that it has entered into definitive agreements with investors for the sale of 2,725,339 shares of common stock at a price of $7.35 per share. Estimated net proceeds to the Company after deducting estimated offering expenses are $18.6 million. RBC Capital Markets served as lead placement agent and Cowen and Company, LLC acted as co-agent.
